Impact of Body Mass Index and Its Dynamic Changes on Response and Survival in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving Endocrine Therapy
International Journal of General Medicine · 2026-11 · Volume 19 · 1-14
DOI: 10.2147/ijgm.s641992 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of General Medicine, 2026-11. Verfasst von Ting Zeng und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To assess the impact of baseline body mass index (BMI) and its dynamic changes on treatment outcomes in patients with hormone receptor (HR)-positive metastatic breast cancer (MBC) receiving endocrine therapy (ET).
Methods
We retrospectively reviewed patients with HR-positive and human epidermal growth factor receptor 2 (HER2)-negative MBC who received ET. Patients were grouped by baseline BMI into low-BMI ( 5%, n=25), BMI-stable (|ΔBMI|≤ 5%, n=35), and BMI-decrease (
Zitieren
APA
Zeng, T., Wang, L., Han, W., & Yuan, Z. (2026). Impact of Body Mass Index and Its Dynamic Changes on Response and Survival in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving Endocrine Therapy. International Journal of General Medicine, Volume 19, 1-14. https://doi.org/10.2147/ijgm.s641992
Vancouver
Zeng T, Wang L, Han W, Yuan Z. Impact of Body Mass Index and Its Dynamic Changes on Response and Survival in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving Endocrine Therapy. International Journal of General Medicine. 2026;Volume 19:1-14. doi:10.2147/ijgm.s641992
BibTeX
@article{Zeng2026,
author = {Zeng, Ting and Wang, Lishuai and Han, Wei and Yuan, Zhiping},
title = {Impact of Body Mass Index and Its Dynamic Changes on Response and Survival in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving Endocrine Therapy},
journal = {International Journal of General Medicine},
year = {2026},
volume = {Volume 19},
pages = {1--14},
doi = {10.2147/ijgm.s641992}
}
EUVIMED